Latest Breaking News On - Lisah lancaster - Page 1 : vimarsana.com

Pliant Therapeutics Inc (PLRX) Presents Data from Bexotegrast Program

Pliant Therapeutics Inc (PLRX) Presents Data from Bexotegrast Program
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesChristopher keenanLisah lancasterAmerican thoracic societyInternational conferenceEuropean medicines agencyPliant therapeutics incDrug administrationCorporate communicationsChief medical officerFavorable safetyIndicates antifibrotic activityIdiopathic pulmonaryVanderbilt university medical centerWith standard of care therapies hasSynergistic effect

Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference

SOUTH SAN FRANCISCO, Calif., May 24, 2023 Pliant Therapeutics, Inc. , a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of. | June 11, 2023

United statesLisah lancasterChristopher keenanPliant therapeutics incInternational conferenceDrug administrationEuropean medicines agencyAmerican thoracic societyCorporate communicationsChief medical officerVanderbilt university medical centerPrincipal scientistPrivate securities litigation reform actPliant therapeuticsFinancial conditionAnnual report

Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Durable Improvement Shown in FVC and Across Multiple Measures

Bexotegrast was well tolerated up to 40 weeks of treatment with no drug-related serious adverse events Combination of bexotegrast with standard of care reduced FVC decline by 80% relative. | April 30, 2023

Lisah lancasterToby maherChristopher keenanLos angelesDrug administrationBexotegrast clinical development nextUniversity of southern californiaCorporate communicationsVanderbilt university medical centerPliant therapeutics incEuropean medicines agencyGroup demonstrated treatment effects including durable improvementsQuantitative lung fibrosisWell toleratedPercent changeCough severity visual analog scale

Pliant Therapeutics Announces Positive Long-Term Data from

Bexotegrast was well tolerated up to 40 weeks of treatment with no drug-related serious adverse events Combination of bexotegrast with standard of care.

Lisah lancasterToby maherLos angelesChristopher keenanGroup demonstrated treatment effects including durable improvementsCorporate communicationsDrug administrationVanderbilt university medical centerEuropean medicines agencyBexotegrast clinical development nextPliant therapeutics incUniversity of southern californiaQuantitative lung fibrosisWell toleratedPercent changeCough severity visual analog scale

Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Durable Improvement Shown in FVC and Across Multiple Measures

Bexotegrast was well tolerated up to 40 weeks of treatment with no drug-related serious adverse events Combination of bexotegrast with standard of care reduced FVC decline by 80% relative. | April 30, 2023

Lisah lancasterChristopher keenanLos angelesToby maherDrug administrationBexotegrast clinical development nextCorporate communicationsGroup demonstrated treatment effects including durable improvementsKeck school of medicineVanderbilt university medical centerUniversity of southern californiaGlobenewswire incPliant therapeutics incEuropean medicines agencyQuantitative lung fibrosisWell tolerated